Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers

To the Editor We read with interest the Original Investigation from Yu et al¹ wherein they reported results of a phase 1/2 trial to assess the effects of the combination of osimertinib and bevacizumab as first-line treatment for patients with metastatic EGFR-mutant lung cancers. However, the 19-month median progression-free survival (PFS) in the study was comparable with the median PFS with osimertinib alone (19 months) in the FLAURA study.² We wish to put forth the following discussion points.